ESMO Archives -

ESMO 2019 roundup

https://pharmaphorum.com/views-analysis-oncology/esmo-2019-roundup/

ESMO 2019 – new data could unlock bigger market for PARP inhibitors

https://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/

ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challenge

https://pharmaphorum.com/news/esmo-2019-amgens-kras-drug-finds-colorectal-cancer-a-challenge/

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data

https://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/

Merck KGaA’s bold new approach to cancer immunotherapy

https://pharmaphorum.com/views-analysis-oncology/merck-kgaas-bold-new-approach-to-cancer-immunotherapy/

ESMO round-up: Big win for AstraZeneca in ovarian cancer, and more

https://pharmaphorum.com/views-and-analysis/esmo-round-up-big-win-for-astrazeneca-in-ovarian-cancer-and-more/

Tagrisso on target to be EGFR+ lung cancer standard

https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/

Rubraca outshines rivals in ovarian cancer maintenance therapy

https://pharmaphorum.com/news/rubraca-outshines-rivals-ovarian-cancer-maintenance/

ESMO 2017 preview: AstraZeneca‘s comeback, IO shifts to earlier use

https://pharmaphorum.com/views-and-analysis/esmo-2017-preview-astrazeneca-s-comeback-io-shifts-earlier-use/

Search